Every 424B that Silence Therapeutics Plc (SLN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow SLN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SLN filings page.
Silence Therapeutics plc is conducting an underwritten public offering of 12,962,963 American Depositary Shares (ADSs), each representing three ordinary shares, at $13.50 per ADS, for gross proceeds of $175,000,000.50. Underwriters have a 30-day option to purchase up to 1,944,444 additional ADSs.
After underwriting discounts and estimated expenses, net proceeds are estimated at about $164.0 million, or $188.7 million if the option is fully exercised. The company plans to use the funds, together with existing cash, to continue clinical development of its siRNA product candidates and for general corporate purposes.
As of June 30, 2026, there were 141,739,180 ordinary shares outstanding (47,246,393 ADSs). The offering will cause immediate dilution of $10.32 per ADS to new investors based on a historical net tangible book value of $0.59 per ADS increasing to $3.18 per ADS after the offering.
Silence Therapeutics plc is conducting a primary offering of up to $150,000,000 of American Depositary Shares, with each ADS representing three ordinary shares. The ADSs trade on the Nasdaq Global Market under the symbol “SLN”.
The company is a biotechnology business developing short interfering RNA (siRNA) therapeutics using its proprietary mRNAi GOLD™ platform to silence disease-associated genes in the liver. It recently announced positive topline Phase 2 SANRECO results for its candidate divesiran and expects to start a Phase 3 Q12W dosing trial in the first half of 2027.
Net proceeds, together with existing cash and cash equivalents, are intended to fund continued clinical development of product candidates and general corporate purposes, including working capital, capital expenditures, investments and collaborations. Management expects this funding, combined with current cash, to support operations and capital needs into 2029, though additional capital is expected to be required to complete development of any product candidate. Investors face risks including immediate dilution, potential future equity offerings, an active-market risk for ADSs, and no anticipated dividends.
Silence Therapeutics plc filed a prospectus supplement to offer up to $100,000,000 of American Depositary Shares (ADSs) under an at-the-market sales agreement with Jefferies LLC dated May 18, 2026. Each ADS represents three ordinary shares. The offering is agent-led: Jefferies may sell ADSs from time to time, subject to market conditions and mutually agreed terms, and is entitled to up to a 3.0% commission. The prospectus notes 47,234,613 ADSs (141,703,840 ordinary shares) outstanding as of March 31, 2026, states an assumed illustrative price of $6.10 per ADS for dilution examples, and discloses net tangible book value metrics (historical $0.82 per ADS, as-adjusted $2.12 per ADS) and illustrative dilution of $3.98 per ADS. Use of net proceeds, if any, is for clinical development and general corporate purposes. The offering may be conducted as an "at-the-market" program and proceeds and number of ADSs sold are uncertain.